Shiji Bio's Preferred Bidder Replaced from IMM PE to TA Associates Over Non-Compete Clause

According to Chosun Biz, on July 7, Shiji Bio, a regenerative medicine subsidiary of Daewoo Group, saw its preferred bidder for management rights acquisition replaced from IMM Private Equity to TA Associates, a U.S.-based private equity firm. The change emerged amid disagreement between Daewoo Pharmaceuticals and IMM PE over non-compete clause terms during final contract negotiations.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments